FDA authorization does not create Medicare coverage; founders need a separate CMS coverage plan long before launch. The CMS TCET pathway can create conditional national Medicare coverage for qualifying devices and diagnostics, but it rewards teams that prepare evidence, benefit-category fit, and reimbursement operations about 18 months before authorization.
If you’re building a medtech, diagnostic, or digital health product that depends on Medicare adoption, TCET should sit beside your Food and Drug Administration (FDA) plan, not behind it. This roadmap shows what to lock down, what to ask the Centers for Medicare & Medicaid Services (CMS), and how to avoid reaching FDA authorization with no coverage path ready.
Why Medicare Coverage Is The Real Gate After FDA Approval
FDA authorization answers one question: whether your product can be marketed for its intended use. Medicare coverage answers a different question: whether CMS will pay for the product or service for Medicare beneficiaries under defined conditions. Founders often merge those two questions in planning decks, but CMS does not treat FDA authorization as automatic coverage.
That separation matters for your launch plan. A device can be authorized and still face slow provider adoption if hospitals, physicians, or diagnostic labs do not see a workable Medicare coverage route. Investors, provider customers, and strategic partners will ask how your product fits a Medicare benefit category, whether claims can be submitted, and what evidence supports reasonable and necessary use.
The practical move is to start coverage planning before FDA authorization is within sight. At 18 months out, you still have room to adjust endpoints, budget for evidence work, brief advisors, and prepare a credible CMS conversation. After authorization, your choices narrow and delays become harder to explain.
What The CMS TCET Pathway Is — And What It Doesn’t Do
The CMS TCET pathway is a voluntary Medicare coverage process for certain FDA-regulated medical devices and diagnostics. It uses Coverage with Evidence Development (CED), which allows conditional coverage as evidence is generated under a CMS-reviewed evidence plan. TCET sits inside Medicare coverage policy; it is not a substitute for FDA review.
TCET is designed around steps that founders can plan for: manufacturer nomination, CMS screening, a pre-submission meeting, evidence preview, draft and final evidence development planning, then a proposed and final National Coverage Determination (NCD) with CED if the product proceeds. Later, CMS can re-evaluate coverage based on the evidence generated. That sequence means your internal work must be ready before the formal steps begin.
TCET also has limits. It does not create a new payment rate, grant a billing code, replace Local Coverage Determinations (LCDs), or guarantee permanent coverage. It also does not cover drugs or biologics. If your launch plan depends on Medicare revenue, you still need coding, payment, site-of-care, provider workflow, and Health Economics and Outcomes Research (HEOR) planning in parallel.
The 18-Month CMS TCET Pathway Preparation Timeline At A Glance
The 18-month window gives you enough time to connect regulatory, clinical, market access, and commercial work without forcing every decision into the final weeks before authorization. Your goal is not to “win TCET” on paper. Your goal is to make sure CMS sees a product with a defined Medicare population, a plausible benefit category, a workable evidence plan, and a team that can execute.
Use this timeline as an operating plan. The timing will vary by product, trial status, FDA pathway, and CMS feedback, but the workstreams stay consistent. Assign owners early so the coverage work does not become a side project passed between clinical, finance, and business development.
18-Month Preparation Timeline
|
Window |
Founder Priority |
Owner To Assign
|
|
Months 18–12 |
Confirm Medicare benefit category, target population, evidence gaps, and FDA pathway fit. |
Chief executive, regulatory lead, market access advisor, clinical lead. |
|
Months 12–6 |
Align real-world evidence, endpoints, coding groundwork, and provider workflow. |
Clinical lead, HEOR advisor, reimbursement consultant, data partner. |
|
Months 6–0 |
Prepare nomination materials, CMS pre-submission questions, and evidence development plan. |
Market access lead, regulatory lead, counsel, clinical operations. |
Months 18–12: Lock Your Medicare Benefit Category And Evidence Strategy
Your first job is to prove that Medicare can cover the product under a recognized benefit category. If your product does not fit, TCET cannot fix that gap for you. This is where many founders lose time: they wait until after FDA authorization to ask whether the product is a physician service, diagnostic test, durable medical equipment item, hospital outpatient technology, or part of another covered service.
Map the beneficiary, setting of care, ordering provider, billing provider, and clinical workflow. A diagnostic used in a lab has a different reimbursement path than an implanted device used in a hospital procedure. A digital health product used by a physician group has different operational questions than a device used by a specialist in an outpatient department.
Then compare your FDA evidence plan with Medicare evidence needs. FDA may focus on safety and effectiveness for the labeled indication, but CMS will care about whether the item or service is reasonable and necessary for Medicare beneficiaries. If your pivotal study underrepresents older adults, comorbid patients, or care settings common in Medicare, your TCET evidence plan may need real-world evidence to close that gap.
Months 12–6: Align Real-World Evidence, Endpoints, And Coding Groundwork
CED means CMS coverage can be tied to evidence generation. For a founder, that turns real-world evidence from a post-launch research idea into a launch-readiness item. You need to define what data you can collect, who will collect it, what outcomes matter, and how the work can run without breaking provider workflow.
Choose endpoints that connect clinical value to Medicare decision-making. That may include patient selection, utilization, clinical outcomes, procedure avoidance, complications, repeat testing, hospital use, or functional outcomes, depending on the product. The point is to connect evidence collection to the coverage question CMS will ask, not just the endpoints your product team prefers.
Start coding and payment groundwork during this same window. TCET can address Medicare coverage, but it does not hand you a Current Procedural Terminology (CPT) code, Healthcare Common Procedure Coding System code, Ambulatory Payment Classification placement, or payment rate. If providers cannot bill cleanly, conditional coverage may still fail commercially.
Months 6–0: Nomination, Pre-Submission Meeting, And Evidence Preview
As you move closer to FDA authorization, your TCET work should become more formal. Prepare your nomination story around eligibility, patient population, unmet need, evidence generated so far, and the remaining evidence questions. Do not send CMS a generic investor narrative. CMS needs a coverage-ready package, not a growth story.
The pre-submission meeting is your chance to test the coverage logic before the process hardens. Bring specific questions: benefit-category fit, population boundaries, evidence gaps, data sources, proposed outcomes, study burden, and timing. The strongest founders use the meeting to reduce ambiguity, not to ask CMS to design the entire plan.
The evidence preview and evidence development plan should be built from materials you have already pressure-tested internally. Your clinical team, regulatory team, HEOR support, and reimbursement advisors should agree on the proposed population, data collection plan, endpoints, and operational burden. If those groups disagree late, CMS will see the cracks.
Founder Mistakes That Derail TCET Timing
The first mistake is treating TCET as a post-authorization paperwork exercise. If you wait until FDA authorization is close, you may discover that your study population, claims path, or care setting does not answer CMS’s coverage questions. At that point, fixing the evidence plan can mean extra cost, launch delay, or a weaker CMS conversation.
The second mistake is confusing coverage with payment. A positive coverage path does not guarantee an adequate payment rate or a usable billing route. Your revenue model should separate four questions: whether Medicare can cover it, what code is used, who bills, and how much payment flows to the provider or facility.
The third mistake is assuming FDA Breakthrough Device designation solves coverage. Breakthrough status may support a TCET fit discussion because TCET is aimed at certain FDA-regulated technologies, but CMS still runs its own coverage analysis. Treat FDA designation as one input, not as a Medicare launch plan.
How To Resource TCET Without A Full Reimbursement Team
Most startups do not need a large in-house reimbursement department 18 months before authorization. They do need named owners. One executive should own CMS readiness, one clinical leader should own evidence alignment, and one finance or commercial leader should own coding and payment assumptions.
Use outside experts with narrow mandates. A reimbursement advisor can test benefit-category fit and coding options. A HEOR advisor can shape the evidence development plan and real-world evidence design. Counsel can help review CMS submissions, but legal review should not replace reimbursement strategy.
Build a small TCET operating file and keep it current. Include your FDA pathway summary, intended use, Medicare patient profile, benefit-category analysis, evidence gap table, draft endpoints, data source options, coding assumptions, and provider workflow notes. This file becomes your source material for CMS meetings, board updates, investor diligence, and partner discussions.
How TCET Should Shape Your Clinical And Commercial Decisions
TCET planning should influence study design before it influences marketing. If your FDA trial does not answer Medicare-relevant questions, add real-world evidence planning early enough to avoid a rushed add-on. The best time to think about registries, claims linkages, follow-up windows, and site readiness is before your clinical operations team is locked into final processes.
Commercial planning should also reflect CED obligations. Providers may support evidence generation if the workflow is manageable and the covered population is clear. They may resist if data capture is vague, staff burden is high, or billing steps are uncertain. Your launch team should test those operational details with provider sites before making adoption claims.
For fundraising, TCET preparation can sharpen the reimbursement story. You can show investors that FDA authorization, Medicare coverage, coding, payment, and evidence generation are separate workstreams with owners and milestones. That does not remove risk, but it shows that the team understands how health care revenue is actually unlocked.
What Should Founders Do 18 Months Before CMS TCET Authorization?
- Confirm Medicare benefit category and FDA pathway fit
- Define real-world evidence endpoints CMS will accept
- Request a CMS pre-submission meeting once eligible
- Draft an evidence development plan early
- Assign coding, payment, and HEOR owners now
Make TCET A Launch-Readiness Workstream, Not A Late Reimbursement Task
The founders who handle CMS TCET pathway planning well do not wait for FDA authorization to start Medicare work. They confirm the benefit category, align evidence with Medicare beneficiaries, prepare for CED, and separate coverage from coding and payment. They also give the work real ownership instead of leaving it to chance after clinical and regulatory milestones are set. If Medicare adoption matters to your business model, the 18 months before authorization are not early; they’re the window where you still have room to build the right plan.
References
- Centers for Medicare & Medicaid Services: Transitional Coverage For Emerging Technologies
- Centers for Medicare & Medicaid Services: TCET Pathway Fact Sheet
- Federal Register: Transitional Coverage For Emerging Technologies Final Notice
- Centers for Medicare & Medicaid Services: Coverage With Evidence Development
- Food and Drug Administration: Breakthrough Devices Program.
Maurizio Chiriva Internati (DBSc, PhDs) is a cancer immunologist and biotech entrepreneur with 20+ years in immuno-oncology. Co-founder and former CEO of Kiromic BioPharma (NASDAQ: KRBP), he has led AI-driven target discovery and translational programs, and has served on faculty at MD Anderson and Texas Tech.
